Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

Phase 3TerminatedNCT00571142

Asociación para Evitar la Ceguera en México20 enrolled

Overview

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diffuse Diabetic Macular Edema

Interventions

Bevacizumab + Pars plana vitrectomyPROCEDURE

2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.

Bevacizumab + pars plana vitrectomyPROCEDURE

2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy

Eligibility

Sex: ALLMin age: 25 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Older than 25 yo * Diffuse diabetic macular edema with or without previous treatment Exclusion Criteria: * Another retinal disease * Pregnancy

Locations (1)

Asociacion para Evitar la Ceguera en Mexico I.A.P.

México, Mexico

Outcomes

Primary Outcomes

Retinal thickness

Time frame: 3 months

Secondary Outcomes

Visual acuity

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.